Longer-Term Safety and Efficacy Measures of AR101 Oral Immunotherapy for Peanut Allergy: Results from a Phase 3 Follow-On Study

Of subjects who completed the phase 3 study of the experimental treatment AR101 for peanut allergy (PALISADE), 76% of AR101-treated subjects vs 5.4% of placebo-treated tolerated ≥600mg of peanut protein at exit double-blind, placebo-controlled food challenge (DBPCFC). Adverse events (AEs) were mostly mild-to-moderate in severity. The ability to tolerate doses >1000 mg and safety beyond the initial maintenance period has not been established and initial findings from the ongoing study are reported.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2MS60c1